Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content

Aims and scope

Aims and scope

Clinical Proteomics encompasses all aspects of translational proteomics. This includes quantitative and qualitative profiling of proteins and peptides that are present in clinical specimens like human tissues and body fluids. Special emphasis is placed on the application of proteomic technology to all aspects of clinical research and molecular medicine.
 
As an open access journal, Clinical Proteomics is committed to rapid scientific review and timely publication of submitted manuscripts. This is achieved by receiving, processing and publishing submissions online. As molecular medicine moves beyond genomics to proteomics, the goal becomes the characterization of the cellular circuitry and the understanding of the impact of disease and therapy on precision medicine.
 
Clinical Proteomicsprovides a scholarly forum for novel scientific research in the field of translational proteomics. The journal is publishing manuscripts with significant scientific discoveries or observations related to human diseases, for example the discovery and analytical and preclinical validation of novel diagnostic or therapy related markers, the potential of protein profiles for the development of personalized medicine. This will include original research articles and reviews in proteomics and bioinformatics. Articles in the development and application of technologies, clinical studies, methodologies, and protocols are also welcome.